September 21, 2016
September 21, 2016
Enteris BioPharma’s “Feasibility to Licensing” Partner, Cara Therapeutics, Advances Peptelligence®-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain Trial to evaluate three tablet strengths of […]
July 13, 2016
July 13, 2016
Enteris BioPharma Initiates Clinical Program for Tobrate™ (oral tobramycin tablet) in Uncomplicated Urinary Tract Infection Tobrate adds to Enteris’ internal product pipeline and complements external, Peptelligence®-powered “feasibility-to-licensing” […]
January 19, 2016
January 19, 2016
Enteris BioPharma Enhances Executive Leadership Team to Target Strategic Growth Opportunities 30+ Year Healthcare Industry Veteran, Joel A. Tune, Appointed as Chief Executive Officer Paul Shields, […]
October 19, 2015
October 19, 2015
Enteris BioPharma’s Formulation Technology Enables Oral Delivery of Tarsa Therapeutics’ TBRIA™ – the First Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis Boonton, NJ – […]
July 14, 2015
July 14, 2015
Enteris BioPharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics’ CR845 Boonton, NJ – July 14, 2015 – Enteris BioPharma, Inc., an industry […]
February 10, 2015
February 10, 2015
Enteris BioPharma Launches Contract Manufacturing within 32,000 Square Foot, FDA inspected and cGMP Compliant Facility Cost-effective, high-quality production of API using microbial expression systems Boonton, […]
December 9, 2014
December 9, 2014
Enteris BioPharma’s Formulation Technology Enables Oral Delivery of Cara Therapeutics’ CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial BOONTON, N.J., Dec. […]
KNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MOREKNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MORE
